|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | National Center for Research Resources (NCRR) |
|---|---|
| Collaborator: |
University of North Carolina |
| Information provided by: | National Center for Research Resources (NCRR) |
| ClinicalTrials.gov Identifier: | NCT00006130 |
Purpose
OBJECTIVES: I. Phase II trial to determine surgical morbidity of decompression coring, including any adverse events in the perioperative period and the rate of secondary medical or surgical interventions.
II. Collect preliminary data to determine if decompression coring results in a substantial improvement in pain and mobility compared to conservative therapy in patients with avascular necrosis of the hip related to sickle cell disease.
| Condition | Intervention |
|---|---|
|
Bone Avascular Necrosis Sickle Cell Anemia |
Procedure: Core decompression |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Primary Purpose: Treatment |
| Official Title: | Randomized Study of Decompression Coring Versus Conservative Therapy in Patients With Avascular Necrosis of the Hip Related to Sickle Cell Disease |
| Estimated Enrollment: | 50 |
| Study Start Date: | June 1999 |
PROTOCOL OUTLINE: This is a randomized, multicenter study. Patients are stratified according to stage of avascular necrosis (I vs II vs III). Patients are randomized into one of two treatment arms.
Arm I: Patients undergo a core biopsy and decompression of the hip followed by a standardized program of touch down or nonweight bearing with appropriate equipment and regular physical therapy for 6 weeks and then full weight bearing if tolerated.
Arm II: Patients undergo the standardized ambulation and physical therapy program as in arm I. They do not undergo any surgical procedure.
For 1 week prior to the beginning of the standardized program and during the 6 weeks of touch down or nonweight bearing, all patients complete a weekly pain and medication diary.
Patients are followed at 3 months and 6 months, then every 6 months for 1.5 years, and then annually for up to 5 years.
Eligibility| Ages Eligible for Study: | 10 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion criteria:
Exclusion criteria:
Contacts and Locations| United States, California | |
| Children's Hospital of Oakland | |
| Oakland, California, United States, 94609 | |
| United States, North Carolina | |
| University of North Carolina School of Medicine | |
| Chapel Hill, North Carolina, United States, 27599-7070 | |
| Study Chair: | Elliott P. Vichinsky | University of North Carolina |
More Information
| ClinicalTrials.gov Identifier: | NCT00006130 History of Changes |
| Other Study ID Numbers: | NCRR-M01RR01271-5715, UNCCH-GCRC-1375 |
| Study First Received: | August 3, 2000 |
| Last Updated: | June 23, 2005 |
| Health Authority: | United States: Federal Government |
|
arthritis & connective tissue diseases avascular necrosis disease-related problem/condition genetic diseases and dysmorphic syndromes |
hematologic disorders pain rare disease sickle cell anemia |
|
Anemia Anemia, Sickle Cell Necrosis Osteonecrosis Hematologic Diseases Anemia, Hemolytic, Congenital |
Anemia, Hemolytic Hemoglobinopathies Genetic Diseases, Inborn Pathologic Processes Bone Diseases Musculoskeletal Diseases |